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ABSTRACT
The histidine decarboxylase inhibitor brocresine, in doses from 600 mg to 1800 mg
daily, failed to diminish skin histamine and histamine excretion in patients with chronic
urticaria. A slight decrease in clinical symptoms was found, these data, however, are
comparable to those found, when chronic urticaria patients are treated with placebo.
No patient was cured after two weeks of treatment. Possible explanations of the lack of
potent inhibition and discrepancies with observations of other workers are discussed.
Recent experiments by Levine (1) have
aroused renewed interest in the inhibition of
histamine biosynthesis in man. In mammalian
tissues histamine is produced by decarboxyla-
tion of histidine. Mammalian histidine decar-
boxylases are of two main types. One type acts
not only on histidine, but also on other
aromatic amino acids, and is named non-specific
aromatic L-amino acid decarboxylase. The sec-
ond type which occurs in mast cells (2), certain
tumors (3), and other rapidly growing tissues
(4) is a specific enzyme acting only on histidine.
Brocresine or NSD 1055, which is a 4-bromo-3-
hydroxybenzyloxyamine-dihydrogen phosphate
has been reported to be an inhibitor of both
types of histidine decarboxylases (1, 5, 6, 7).
This paper reports on analyses of urinary
and skin histamine in chronic urticaria before
and during treatment with brocresine. The
possible clinical effect of brocresine was also
studied.
MATERIAL AND METHODS
The study included six men and ten women
suffering from chronic urticaria. All patients had
symptoms for more than three months. Before
treatment, a general medical examination was
performed and found to be normal. The laboratory
examination included hemoglobin, leukocyte and
differential counts, eosinophil and platelet counts,
serum glutamic pyruvic transaminases (SGPT),
serum creatine, potassium, sodium, chloride and
Co,, as well as urinalysis. All examinations were
repeated after termination of the study. The urine
was analysed weekly for protein and sugar. Leuko-
cytes, platelets, and SGPT were also examined
weekly. The blood pressure was measured daily
through two weeks as well as after termination of
the study. Two patients received treatment
through fourteen weeks and two other patients
through ten weeks. In one patient the study was
discontinued after one week. The remaining eleven
patients were treated for two weeks.
Brocresinet was given orally in three or four
daily doses. The patients received from 600 mg to
1800 mg daily (10—30 mg per kg). In eleven pa-
tients, urinary histamine was measured before
treatment and on the seventh, eighth, thirteenth
and fourteenth day of treatment. Two patients
had their urinary histamine measured after two
months of treatment and two other patients after
three months of treatment. Skin histamine was in-
vestigated in twelve patients before and after two
weeks of treatment. The patients treated through
ten or fourteen weeks had further analyses before
the termination of treatment. All specimens were
from grossly normal non-weahing skin. Histamine
was determined spectrofluorometrically (8, 9).
The clinical response was evaluated in all pa-
tients by giving daily scores through two weeks for
severity of disease and severity of itch. Scores for
grading were 0 none, 1 = mild, 2 moderate
and 3 = severe. Possible side-effects were registered
simultaneously.
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RESULTS
Figure 1 displays results of the first two
weeks of clinical investigation. Within the first
week of study, a moderate decline in total
score for severity of disease and for itch could
be demonstrated. During the following week the
total scores remained almost constant. The
clinical condition was improved in six patients
after two weeks of treatment and in three of
the four patients, who continued therapy for
t Generously supplied by Smith & Nephew Ltd.
through Pharmacia A/S, Copenhagen, Denmark.
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FIG. 1. Total score for urticaria and itch in 15
patients with chronic urticaria during two weeks
of treatment with brocresine, 600—1800 mg per day.
Individual scores for grading were 0 = none, 1
mild, 2 moderate, and 3 severe.
TABLE I
Mean urinary histamine per i4 hours in 10 patients
with chronic urticaria, before and during first two
weeks of treatment with brocresine, 600—1800 mg
daily. One patient with excessive histamine excre-
tion excluded
Day of treatment Urinary histamine SE.(.g/24 hr.)
—2
—1
7
8
13
14
57±5
53±6
58±15
44±6
47±3
46±4
ten or fourteen weeks. In one patient, treated
through fourteen weeks, urticaria was com-
pletely unchanged.
Brocresine failed to diminish histamine ex-
cretion significantly (Table I). One patient
with a very severe urticaria and angioneurotic
edema displayed greatly increased urinary
histamine values (1619 eg/24 h) before therapy
and more moderately increased values (736 and
485 jsg/24 h) after thirteen and fourteen days
of treatment.. When this patient was excluded,
the mean urinary histamine was found within
normal levels (15—90 fcg/24 h) (8). Histamine
excretion after ten or fourteen weeks of treat-
ment is visualized on Table II.
No significant decrease of histamine could be
found in non-wealing, grossly normal skin,
either after two weeks of treatment (Table III)
TABLE II
Urinary histamine per t4 hours in 4 patients with
chronic urticaria before and during ten or four-
teen weeks of treatment with brocresine, L600—
1800 mg daily
Urinary histamine (g/24 hr.)
TABLE III
Skin histamine levels in grossly normal dried and
defatted thigh skin of 1 patients with chronic
urticaria before and after two weeks' treatment
with brocresine
Skin histamine (jg/g)
Mean S.E. 23.7 2.5 20.6 1.8
Score
30 x x Urticaria
.—. Itch
20
15
10
5
8 9 1011 121314 days
Before After
treat- 1
ment week
80 53
81 31
Sex/ Dosage
Age (mg/day)
M/52 1800
F/40 1800
F/37 1800
F/26 1200
After
10
weeks
65
50
36
55
After
weeks
44
40
55
55
52
52
44
40
After
14
weeks
34
25
32
27
46
24
32
39
41
32
15
17
30
37
178
31
Sex/Age
M/68
F/56
F/33
M/43
F/26
M/41
F/26
M/44
F/69
F/37
F/36
F/24
Dosage(mg/day)
600
600
600
1200
1200*
1200
1200
1600
1200
1800
1200*
1200
Before
treatment
19.4
21.2
17.8
44.6
21.5
13.4
14.1
18.4
27.1
29.7
27.1
29.8
After
treatment
16.4
19.9
15.6
22.0
18.2
10.8
16.4
20.2
19.8
28.1
27.2
32.6
* During second week of treatment 1600 mg
brocresine per day.
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TABLE IV
,Skin histamine levels in grossly normal dried and
defatted thigh skin of 4 patients with chronic
urticaria before and after ten or fourteen weeks of
treatment with brocresine, 1800—1800 mg per day
Skin histamine
Sex/Age Dosage(mg/day)
Duration of
treatment
(weeks)
(Lg/g)
Before After
treat- treat-
ment ment
M/52 1800 10 32.0 42.1
F/40 1800 10 34.6 35.9
F/37 1800 14 29.7 32.6
F/26 1200 14 17.4 33.4
or after treatment for ten or fourteen weeks
(Table IV).
In one patient, treatment was discontinued
after one week due to a slightly elevated
SGPT, which rose from 0.5 units per ml to 2.3
units per ml. After cessation of therapy, the
values returned to normal within a week. No
other side effects were demonstrated by labo-
ratory examination. Subjective side effects were
mild sedation and weariness in one patient and
headache in another patient. This patient, how-
ever, admitted having frequent headaches prior
to treatment.
DISCUSSION
The clinical data presented are comparable to
those found when chronic urticaria patients
are treated with placebo (10). None of our pa-
tients were cured after two weeks of treatment.
The results of this study contrast with those
of Levine (1), who studied the effect of
brocresine on two men without any abnor-
mality in histamine metabolism and on two
women with extensive systemic mastocytosis.
Inhibited biosynthesis of histamine was dem-
onstrated in all four subjects. The studies,
however, are not comparable, because Levine
used histidine loading. Our data agree with the
findings of Demis (11), who failed to diminish
histamine excretion by brocresine in patients
with systemic mast cell disease. In studies on
rats Johnston and Kahison (12) found that a
single injection of brocresine gave a 54 per
cent inhibition of histamine formation when
this was judged by the output of isotopic
histamine after injection of 14 C histidine.
However, only repeated injections of bro-
cresine gave a moderate degree of inhibition
when a non-isotopic method was employed.
They proposed that, for unknown reasons,
brocresine interferes more readily with conver-
sion of injected histidine than with the sub-
strate normally contained in the cells. This
may account for the negative results of the
present study. Our data on skin histamine con-
firm the lack of potent inhibition of histamine
formation by brocresine in man. The data on
skin histamine are in accordance with studies
by Green and Erickson (13), who found no
significant change in rat heart histamine con-
centration after brocresine. Our study has
shown no clear evidence of toxicity and a
notable absence of side effects in most cases.
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